Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades,
the systemic management of muscle‐invasive and advanced bladder cancer has primarily …

Bladder cancer remains one of the most deadly and expensive diseases affecting modern
society. The options currently available to patients with muscle-invasive bladder cancer …

Bladder cancer is the 10th most common cancer type in the world. There were more than
573,000 new cases of bladder cancer in 2020. It is the 13th most common cause of cancer …

Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Muscle-invasive bladder cancer is an aggressive disease associated with high morbidity
and mortality. Radical cystectomy is the mainstay of treatment and has evolved since the first …

Despite an increased use of neoadjuvant and adjuvant chemotherapy, the long-term
survival rates after radical cystectomy or trimodal therapy (TMT) for muscle-invasive bladder …

Importance Bladder cancer is a common malignancy in women and is the fourth most
common malignancy in men. Bladder cancer ranges from unaggressive and usually …

The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide
recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with …

Purpose of Review BCG is the gold standard agent used in high-risk non-muscle-invasive
bladder cancer (NMIBC) that is amenable to bladder sparing management. However, recent …

Background Chemotherapy is a first-line treatment for advanced and metastatic bladder
cancer, but the unsatisfactory objective response rate to this treatment yields poor 5-year …